MA28290A1 - Procede de preparation - Google Patents

Procede de preparation

Info

Publication number
MA28290A1
MA28290A1 MA29179A MA29179A MA28290A1 MA 28290 A1 MA28290 A1 MA 28290A1 MA 29179 A MA29179 A MA 29179A MA 29179 A MA29179 A MA 29179A MA 28290 A1 MA28290 A1 MA 28290A1
Authority
MA
Morocco
Prior art keywords
preparation
oxo
thiophenecarboxamide
oxiranylmethyl
morpholinone
Prior art date
Application number
MA29179A
Other languages
English (en)
Inventor
Mathias Berwe
Christian Thomas
Joachim Rehse
Dirk Grotjohann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34716548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28290(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA28290A1 publication Critical patent/MA28290A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Procédé de préparation La présente invention se rapporte à un procédé de préparation du 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]-l,3-oxazolidine-5-yl}méthyl)-2-thiophènecarboxamide à partir du 2-[(2S)-2-oxiranylméthyl]-lH-isoindole-l,3(2H)-dione, de la 4-(4-aminophényl)-3-morpholinone et du chlorure de 5-chlorothiophène-2-carbonyl.
MA29179A 2004-01-15 2006-07-10 Procede de preparation MA28290A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004002044A DE102004002044A1 (de) 2004-01-15 2004-01-15 Herstellverfahren

Publications (1)

Publication Number Publication Date
MA28290A1 true MA28290A1 (fr) 2006-11-01

Family

ID=34716548

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29179A MA28290A1 (fr) 2004-01-15 2006-07-10 Procede de preparation

Country Status (33)

Country Link
US (1) US7351823B2 (fr)
EP (1) EP1720866B1 (fr)
JP (2) JP5311742B2 (fr)
KR (1) KR20130004257A (fr)
CN (1) CN1906191B (fr)
AR (1) AR047389A1 (fr)
AT (1) ATE518856T1 (fr)
AU (1) AU2004313694B2 (fr)
BR (1) BRPI0418405B8 (fr)
CA (1) CA2553237C (fr)
CY (1) CY1112565T1 (fr)
DE (1) DE102004002044A1 (fr)
DK (1) DK1720866T3 (fr)
EC (1) ECSP066703A (fr)
ES (1) ES2369140T3 (fr)
GT (1) GT200400277A (fr)
HK (1) HK1103722A1 (fr)
HN (1) HN2005000016A (fr)
HR (1) HRP20110796T1 (fr)
IL (1) IL176767A (fr)
MA (1) MA28290A1 (fr)
MY (1) MY138944A (fr)
NO (1) NO335553B1 (fr)
NZ (1) NZ548506A (fr)
PE (1) PE20050763A1 (fr)
PL (1) PL1720866T3 (fr)
PT (1) PT1720866E (fr)
RU (1) RU2383540C2 (fr)
SI (1) SI1720866T1 (fr)
TW (1) TWI340137B (fr)
UY (1) UY28718A1 (fr)
WO (1) WO2005068456A1 (fr)
ZA (1) ZA200605747B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (fr) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
RU2429236C2 (ru) * 2005-10-04 2011-09-20 Байер Шеринг Фарма Акциенгезельшафт Новая полиморфная форма и аморфная форма 5-хлор-n-({(5s)-2-оксо-3-[4-(3-оксо-4-морфолинил)-фенил]-1, 3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2009018807A1 (fr) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinones utilisées comme inhibiteurs du facteur xa, procédé pour leur production et leur utilisation thérapeutique
US8706950B2 (en) 2008-03-01 2014-04-22 Kabushiki Kaisha Toshiba Memory system
DE102008028071A1 (de) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
US8309547B2 (en) * 2009-04-28 2012-11-13 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US8435989B2 (en) * 2009-04-28 2013-05-07 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
SI2459555T1 (sl) 2009-07-31 2022-03-31 Krka, D.D., Novo Mesto Postopek kristalizacije rivaroksabana
WO2011080341A1 (fr) * 2010-01-04 2011-07-07 Enantia, S.L. Procédé de préparation de rivaroxaban et ses intermédiaires
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
EP2388260A1 (fr) * 2010-05-21 2011-11-23 Archimica GmbH Procédé de fabrication pour un inhibiteur d'un facteur de coagulation sanguine
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
EP2404920A1 (fr) 2010-07-06 2012-01-11 Sandoz AG Form cristalline de Rivaroxaban dihydrate
US20130253187A1 (en) 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) * 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
EP2630143B1 (fr) 2010-10-18 2017-11-29 Apotex Pharmachem Inc. Procédés de préparation de rivaroxaban et ses intermédiaires
GEP20156397B (en) * 2011-05-06 2015-11-10 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Process for the preparation of a rivaroxaban and intermediates formed in said process
WO2012156983A1 (fr) * 2011-05-16 2012-11-22 Symed Labs Limited Procédés pour la préparation de 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phényl]-1,3-oxazolidin-5-yl}méthyl)-2-thiophènecarboxamide
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN102250076A (zh) * 2011-05-27 2011-11-23 横店集团家园化工有限公司 一种利伐沙班中间体及利伐沙班的制备方法
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
WO2013098833A2 (fr) 2011-09-08 2013-07-04 Cadila Healthcare Limited Procédés et intermédiaires destinés à la préparation de rivaroxaban
WO2013053739A1 (fr) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Procédé de préparation d'inhibiteurs du facteur xa
US20150011756A1 (en) * 2012-02-06 2015-01-08 Megafine Pharma (P) Ltd Process for preparation of rivaroxaban and intermediates thereof
CZ2012114A3 (cs) * 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
CN102659756A (zh) * 2012-04-01 2012-09-12 南京哈柏医药科技有限公司 5-氯-2-酰氯噻吩的合成方法
EP2834235A1 (fr) 2012-04-06 2015-02-11 Indiana University Research and Technology Corporation Procédés de préparation du rivaroxaban
AU2012378913B2 (en) 2012-05-02 2017-04-13 Symed Labs Limited Improved process for preparing rivaroxaban using novel intermediates
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
WO2014020458A1 (fr) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Procédé amélioré de préparation du rivaroxaban
CN102786516B (zh) * 2012-08-21 2014-10-01 湖南师范大学 一种利伐沙班的合成方法
CN103833724A (zh) * 2012-11-20 2014-06-04 上海医药工业研究院 一种5-氯噻吩-2-甲酰氯的制备方法
CN103864771A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班的制备方法
CN103864772A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班及其中间体的制备方法
SI3309158T1 (sl) 2012-12-21 2023-12-29 Krka, Tovarna Zdravil D.D., Novo Mesto Rivaroksaban kristalne oblike K in postopek njegove priprave
MX2015003319A (es) 2012-12-26 2015-08-14 Wanbury Ltd Derivado de aldehido de oxazolidinonas sustituidas.
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof
US9663505B2 (en) 2013-03-25 2017-05-30 Glenmark Pharmaceuticals Limited Process for the preparation of rivaroxaban
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
CN103275061A (zh) * 2013-06-04 2013-09-04 上海同昌生物医药科技有限公司 一种生产5-氯噻吩-2-羧酸的方法
CN103351385A (zh) * 2013-06-28 2013-10-16 浙江燎原药业有限公司 一种利伐沙班中间体的制备方法
CN103709116B (zh) * 2013-12-10 2015-09-23 四川大学 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103724336B (zh) * 2013-12-24 2015-10-21 悦康药业集团有限公司 一种新型抗凝血药物的合成方法
WO2015104605A1 (fr) 2014-01-08 2015-07-16 Wockhardt Limited Procédé de préparation de rivaroxaban ou d'un sel pharmaceutiquement acceptable de ce dernier
IN2014CH00290A (fr) 2014-01-23 2015-08-14 Symed Labs Ltd
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
CN105693746B (zh) * 2014-06-14 2018-09-14 广东东阳光药业有限公司 噁唑烷酮类化合物的制备方法及其中间体
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN104211694A (zh) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 一种改进的制备Xa因子抑制剂的方法
WO2016030669A1 (fr) * 2014-08-25 2016-03-03 Cipla Limited Procédé de préparation du rivaroxaban
PL3209661T3 (pl) 2014-10-22 2021-08-16 Zakłady Farmaceutyczne Polpharma Sa Sposób wytwarzania polimorfu rywaroksabanu
CN104807934B (zh) * 2015-04-30 2017-01-18 成都百裕制药股份有限公司 异吲哚二酮类化合物的正相高效液相色谱检测方法
CN105130976A (zh) * 2015-08-26 2015-12-09 浙江车头制药股份有限公司 一种利伐沙班中间体的合成方法
CN105440028B (zh) * 2015-12-07 2018-03-13 石家庄康贺威药业有限公司 一种利伐沙班化合物及其制备方法
CN106008490B (zh) * 2016-01-11 2019-01-04 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
CN106977507A (zh) * 2017-04-21 2017-07-25 上海华源医药科技发展有限公司 一种利伐沙班的制备方法
CN109553611A (zh) * 2017-09-23 2019-04-02 齐鲁制药有限公司 利伐沙班中间体的制备方法和用途
IL275443B (en) * 2018-02-26 2022-07-01 Sumitomo Chemical Co Production method for an oxazolidinan compound
JP7339754B2 (ja) * 2019-03-27 2023-09-06 ダイト株式会社 中間体の製造方法
CN112521380A (zh) * 2020-12-14 2021-03-19 哈尔滨珍宝制药有限公司 一种利伐沙班中间体a的合成方法及其在制备利伐沙班中的应用
EP4347599A1 (fr) * 2021-05-28 2024-04-10 Merck Sharp & Dohme LLC Synthèse d'inhibiteur de btk et ses intermédiaires
EP4201933A1 (fr) * 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Processus de cristallisation de rivaroxaban

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

Also Published As

Publication number Publication date
CN1906191A (zh) 2007-01-31
HK1103722A1 (en) 2007-12-28
HRP20110796T1 (hr) 2011-12-31
JP2007517816A (ja) 2007-07-05
UY28718A1 (es) 2005-08-31
DK1720866T3 (da) 2011-11-21
WO2005068456A1 (fr) 2005-07-28
ATE518856T1 (de) 2011-08-15
KR20130004257A (ko) 2013-01-09
US7351823B2 (en) 2008-04-01
GT200400277A (es) 2005-08-18
HN2005000016A (es) 2009-06-01
PE20050763A1 (es) 2005-12-02
NO335553B1 (no) 2014-12-29
PL1720866T3 (pl) 2012-01-31
BRPI0418405B1 (pt) 2018-03-13
ES2369140T3 (es) 2011-11-25
SI1720866T1 (sl) 2012-01-31
NZ548506A (en) 2009-06-26
CN1906191B (zh) 2010-05-26
CY1112565T1 (el) 2016-02-10
RU2383540C2 (ru) 2010-03-10
AR047389A1 (es) 2006-01-18
JP5311742B2 (ja) 2013-10-09
BRPI0418405B8 (pt) 2021-05-25
TW200604195A (en) 2006-02-01
JP2012097106A (ja) 2012-05-24
TWI340137B (en) 2011-04-11
IL176767A0 (en) 2006-10-31
CA2553237A1 (fr) 2005-07-28
EP1720866A1 (fr) 2006-11-15
NO20063677L (no) 2006-10-11
AU2004313694B2 (en) 2011-06-02
EP1720866B1 (fr) 2011-08-03
PT1720866E (pt) 2011-10-12
MY138944A (en) 2009-08-28
ECSP066703A (es) 2006-10-31
RU2006129341A (ru) 2008-02-20
BRPI0418405A (pt) 2007-05-15
AU2004313694A1 (en) 2005-07-28
IL176767A (en) 2011-04-28
ZA200605747B (en) 2007-10-31
US20050182055A1 (en) 2005-08-18
DE102004002044A1 (de) 2005-08-04
CA2553237C (fr) 2012-04-17

Similar Documents

Publication Publication Date Title
MA28290A1 (fr) Procede de preparation
NO20082059L (no) Ny polymorf form og den amorfe formen av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid
MY138386A (en) Process for the preparation of a solid, orally administrable pharmaceutical composition
ATE545645T1 (de) Neue cokristall-verbindung von rivaroxaban und malonsäure
HK1130252A1 (en) Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders
TW200637558A (en) Solid, modified-release pharmaceutical dosage forms which can be administered orally
CR20150001A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil) fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
UA84399C2 (en) Process for the preparation of 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one
CU23445A3 (es) Procedimiento de preparación
DOP2004001066A (es) Procedimiento de preparacion
UA107446C2 (uk) Спосіб одержання поліморфної форми 5-хлор-n-({(5s)-2-okco-3-[4-(3-okco-4-морфолініл)феніл]-1,3-оксазолідин-5-іл}метил)-2-тіофенкарбоксаміду у модифікації іі
IN2012MU03359A (fr)
UA84591C2 (en) Process for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
TH79777B (th) กระบวนการเตรียม
UY28628A1 (es) Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente